The study team is looking for children ages 6 to under 12 who have severe alopecia areata. The goal is to find out if ritlecitinib is safe and works well to treat this condition.
In this study we want to learn how well a cream called Ruxolitinib works to treat vitiligo on the face and body of children between 2 and 12 years old.